TL;DR
The master antioxidant every cell makes. NAC is its acetaminophen-antidote precursor. Wellness clinics sell it as an IV drip.
What: Tripeptide γ-L-glutamyl-L-cysteinyl-glycine. 307 Da. Unusual γ-peptide bond resists proteases. CAS 70-18-8.
Does: Donates electrons to neutralize ROS and peroxides. Conjugates toxins for biliary and renal excretion. Inhibits tyrosinase, shifting melanin from eumelanin to pheomelanin. That's the skin-lightening mechanism.
Evidence: Richie 2015 RCT (PMID 24791752): 250 or 1,000 mg oral over 6 months raised body stores in 54 adults. Sonthalia 2018 review: modest skin-lightening. Sechi 1996 Parkinson's pilot (n=9) showed motor improvement; blinded follow-ups were mixed.
Used by: Emergency rooms for acetaminophen overdose. Wellness clinics for IV infusions. Asian dermatology for skin-tone outcomes. Liposomal oral at home.
Bottom line: Real drug at the biochemistry level. Real industry at the marketing level. Acetaminophen evidence doesn't transfer to the fatigue-IV claim.
What It Is
Glutathione (GSH) is the tripeptide γ-L-glutamyl-L-cysteinyl-glycine — a naturally occurring molecule synthesized in every human cell. It is the most abundant intracellular thiol antioxidant (millimolar concentrations in most cells) and is the central hub of the body's endogenous antioxidant and Phase II detoxification machinery. The unusual γ-peptide bond between glutamate and cysteine (rather than the α-peptide bond of standard peptides) resists degradation by most proteases and gives glutathione its characteristic stability in the cytosol.
Glutathione exists in two interconverting forms: reduced glutathione (GSH, the active antioxidant form with a free thiol) and oxidized glutathione (GSSG, a dimer formed when two GSH molecules donate electrons). The GSH / GSSG ratio in a given tissue is one of the most informative indicators of cellular redox status: a high ratio indicates a well-defended cell; a collapsed ratio indicates oxidative crisis. The enzyme glutathione reductase uses NADPH to regenerate GSH from GSSG, which is why glutathione and the NAD / NADP system are so tightly coupled.
Glutathione levels decline with age, chronic inflammation, poor diet, toxin exposure, and illness. Low glutathione has been documented in Parkinson's disease (substantia nigra depletion), chronic liver disease, HIV, cystic fibrosis, and normal aging. Restoring optimal glutathione is one of the foundational interventions in the integrative-medicine and wellness-clinic space. In endocrine and critical-care medicine, the role of glutathione is most commercially visible through its precursor N-acetylcysteine (NAC) — an FDA-approved drug (Mucomyst, and generic IV and oral forms) used as the antidote for acetaminophen overdose.
The delivery method matters enormously with glutathione. Orally administered reduced glutathione has historically poor systemic bioavailability because the γ-glutamyl bond that makes it stable in the cytosol is broken in the intestinal brush border by γ-glutamyl transpeptidase, and the cysteine and glycine are absorbed separately. That led to decades of skepticism about oral glutathione — resolved partly by the development of liposomal formulations (which protect the tripeptide through the gut) and partly by the 2015 Richie et al. randomized trial demonstrating that oral glutathione at 250 mg or 1,000 mg/day raised body stores of glutathione (RBC, plasma) over six months. For faster and more quantitative systemic delivery, IV administration is the standard in wellness-clinic practice.
Mechanism of Action
- Direct ROS scavenging — GSH donates electrons from its cysteine thiol to neutralize reactive oxygen species, hydrogen peroxide (via glutathione peroxidase), and lipid peroxides. In doing so, GSH becomes oxidized to GSSG, which is recycled back to GSH by glutathione reductase using NADPH. The GSH / GSSG ratio is a key cellular-redox indicator.
- Phase II hepatic detoxification — Glutathione conjugation via glutathione S-transferases (GSTs) is the primary Phase II liver detoxification pathway. It binds electrophilic xenobiotics, drugs, heavy metals, and carcinogens to form water-soluble mercapturic acid conjugates excreted via bile and urine. This is the mechanism by which the body eliminates acetaminophen's toxic NAPQI metabolite, environmental pollutants, and heavy metals.
- Acetaminophen antidote (NAC → GSH) — The FDA-approved antidote for acetaminophen overdose is N-acetylcysteine (NAC), which provides the rate-limiting cysteine for hepatic glutathione resynthesis. Restoring glutathione neutralizes NAPQI before it damages hepatocytes. This is the single most clinically consequential pharmacology in the glutathione system.
- Immune function — Glutathione is essential for lymphocyte proliferation, NK-cell cytotoxicity, and neutrophil respiratory burst. Immune cells have particularly high glutathione requirements, and depletion impairs both innate and adaptive immunity.
- Mitochondrial protection — Mitochondria produce the most reactive oxygen species and are highly vulnerable to oxidative damage. Mitochondrial glutathione (mGSH) protects the electron transport chain, limits cardiolipin peroxidation, and prevents mitochondrial DNA damage.
- Melanin regulation (skin-lightening mechanism) — Glutathione inhibits tyrosinase (the rate-limiting enzyme in melanin synthesis) and shifts melanin production from eumelanin (dark) to pheomelanin (light) via the cysteine side chain of the tripeptide. This is the mechanistic basis for the widely documented skin-brightening effect of oral, topical, and IV glutathione.
- Vitamin C and vitamin E regeneration — Glutathione participates in the cooperative antioxidant network by regenerating oxidized vitamin C (dehydroascorbate back to ascorbate) and indirectly supporting vitamin E recycling. Vitamin C in turn helps regenerate glutathione from GSSG — the two antioxidants support each other in reciprocal cycles.
- Cysteine reserve function — Glutathione is the body's largest reservoir of labile cysteine, which is the rate-limiting amino acid for numerous sulfur-containing biochemical pathways (taurine synthesis, coenzyme A synthesis, sulfation reactions).
What the Research Shows
- Acetaminophen overdose (NAC precursor) — IV and oral NAC are the FDA-approved standard-of-care antidote for acetaminophen toxicity, working by supplying cysteine for hepatic glutathione resynthesis. This is the single most clinically evidence-backed element of glutathione biology (decades of clinical use in emergency medicine and toxicology).
- Oral glutathione raises body stores (Richie 2015, PMID 24791752) — A 6-month randomized, double-blind, placebo-controlled trial (n=54) of oral glutathione 250 mg or 1,000 mg daily demonstrated dose-dependent increases in plasma, erythrocyte, and lymphocyte glutathione levels, with associated NK-cell cytotoxicity increase at the higher dose. This resolved long-standing skepticism that oral glutathione cannot reach systemic circulation.
- Skin lightening (Sonthalia 2018 review) — Multiple small randomized trials of oral, topical, and IV glutathione report reductions in melanin index and measurable improvements in skin tone. The Sonthalia et al. 2018 review in the Indian Journal of Dermatology, Venereology and Leprology summarizes the evidence — real effect, modest magnitude, dose-dependent, reversible on discontinuation.
- Early Parkinson's disease (Sechi 1996, PMID 8992335) — Sechi G et al. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 1996;20(7):1159-1170. Open-label pilot (n=9) reporting motor-symptom improvement. Subsequent larger randomized trials (Hauser 2009 double-blind placebo-controlled; Mischley 2015 intranasal) have shown more ambiguous results — the Parkinson's evidence is intriguing but not yet definitive.
- Respiratory applications (cystic fibrosis, COPD) — Nebulized glutathione has been evaluated in cystic fibrosis with modest lung-function improvements in some studies. Bishop 2005 / 2014 Cochrane reviews have been cautious about effect-size durability and clinical significance.
- Aging and oxidative stress — Observational studies link higher erythrocyte glutathione to lower biological age and slower cognitive decline. Intervention trials showing durable mortality or disability benefit have not been performed at scale.
- Chronic liver disease — Glutathione and NAC have been studied in non-alcoholic fatty liver disease, alcoholic liver disease, and viral hepatitis. Supportive but not disease-modifying at typical doses.
- IV wellness-clinic literature — IV glutathione, often paired with vitamin C or NAD+, is administered in thousands of wellness clinics worldwide. Efficacy for most target complaints (fatigue, brain fog, post-viral recovery) is supported by mechanism and observational experience rather than large RCTs.
Research Limitation — Heterogeneous Evidence Base
Glutathione evidence spans the full spectrum: strong (NAC for acetaminophen overdose), moderate (oral supplementation raises body stores; skin lightening), suggestive (Parkinson's, respiratory), and wellness-clinic anecdotal (fatigue, detox, post-viral). Generalizing from one indication to another is a common marketing error. Evidence quality varies by application.
Human Data
Unlike many peptides in this database, glutathione has substantial human data — driven by its endogenous role and by decades of clinical use via the NAC precursor pathway.
- Acetaminophen overdose (NAC) — Thousands of patients treated globally with IV or oral NAC per acetaminophen-overdose protocols. FDA-approved label indication for Acetadote (IV NAC).
- Richie 2015 (PMID 24791752) — 54 healthy adults; 250 mg or 1,000 mg oral glutathione daily for 6 months. Dose-dependent increases in RBC, plasma, and lymphocyte glutathione. NK-cell cytotoxicity increase at higher dose.
- Witschi 1992 (PMID 1362956) — Healthy-volunteer study of oral glutathione bioavailability. Early skepticism paper documenting poor systemic delivery of standard oral tripeptide — context for the later liposomal formulation development.
- Sechi 1996 Parkinson's pilot (PMID 8992335) — n=9 early Parkinson's patients; open-label IV glutathione. Motor-symptom improvement reported.
- Skin-lightening RCTs — Multiple randomized trials in Asia and South Asia (Handog 2012, Weschawalit 2017, Arjinpathana 2012, among others) and the Sonthalia 2018 review confirm modest but real skin-lightening effects with oral or IV glutathione; topical glutathione also shows effect with direct skin delivery.
- Cystic fibrosis nebulized trials — Bishop, Hartl, and others have evaluated nebulized glutathione in CF. Mixed results; included in some palliative regimens.
- Wellness-clinic IV use — Thousands of providers globally administer IV glutathione at doses of 600–2,000 mg per infusion, often paired with vitamin C or NAD+. Safety record has been clean at typical doses.
- No large Phase 3 outcomes trial for anti-aging — The aging-biomarker glutathione literature is epidemiological rather than interventional at scale.
Dosing from the Literature
Glutathione is administered through several routes, each with different bioavailability and typical dose ranges.
| Route | Dose | Frequency | Notes |
|---|
| IV push | 600–2,000 mg | 1–2x per week | Most direct systemic delivery. Common in wellness clinics, often paired with NAD+ or vitamin C IVs. 5-minute slow push or 30-minute drip depending on protocol. |
| Subcutaneous / IM | 200–600 mg | 2–3x per week | Available from compounding pharmacies. More practical than IV for ongoing use; slower absorption than IV. |
| Liposomal oral | 500–1,000 mg | Daily | Liposomal encapsulation bypasses gut hydrolysis; Richie 2015 dose range. Practical at-home option. |
| Standard oral glutathione | 250–1,000 mg | Daily | Historically skeptical about bioavailability; Richie 2015 showed measurable body-store increases at 250 mg and 1,000 mg / day over 6 months. |
| Nebulized | 300–600 mg in sterile saline | 1–2x daily | For respiratory applications (CF, chronic bronchitis). Compounded for delivery. |
| NAC (precursor) | 600–1,800 mg | Daily | Provides cysteine for endogenous glutathione synthesis. Well-studied, widely available as OTC supplement; FDA-approved as IV / oral drug (Mucomyst). |
| Acetaminophen overdose (NAC IV, emergency) | Loading 150 mg/kg, then 50 mg/kg + 100 mg/kg | 21-hour protocol | FDA-approved acetaminophen-overdose antidote protocol. Emergency-medicine standard of care. |
Dosing Disclaimer
The NAC-for-acetaminophen-overdose protocol is the only FDA-approved dosing regimen in the glutathione system. Wellness-clinic IV glutathione doses are based on compounded-drug experience and small trial ranges, not formal dose-finding studies. Oral supplementation doses draw from the Richie 2015 RCT (250 mg and 1,000 mg validated). Topical and IV skin-lightening doses vary widely across the Sonthalia 2018 review.
Reconstitution & Storage
Compounded injectable glutathione is typically supplied as a sterile solution (200 mg/mL) in multi-dose or single-dose vials, not as a lyophilized powder. Nebulized glutathione is compounded in sterile saline. Oral liposomal glutathione is supplied as a ready-to-use liquid or soft-gel capsule.
| Format | Presentation | Storage | Typical Daily Pull |
|---|
| Compounded IV solution 200 mg/mL | Sterile ready-to-use | 2–8°C refrigerated | 3–10 mL (600–2,000 mg) per infusion |
| Compounded SubQ 200 mg/mL | Sterile ready-to-use | 2–8°C refrigerated | 1–3 mL (200–600 mg) per injection |
| Nebulized solution | Compounded in sterile saline | 2–8°C, use within 30 days opened | 300–600 mg per treatment |
| Liposomal oral liquid | Ready-to-use | 2–8°C after opening | 5 mL (500–1,000 mg) |
- Oxidation sensitivity — Reduced glutathione (GSH) is thiol-containing and oxidizes on exposure to air. Injectable solutions are typically formulated with preservatives and air-free vials. Discard if the solution turns yellow (oxidation indicator).
- Light sensitivity — Store out of direct light. Refrigerated storage extends stability of reconstituted and compounded products.
- IV compatibility — Compatible with saline carrier. Some wellness-clinic protocols combine in the same IV bag as vitamin C or NAD+; check compounding-pharmacy compatibility data for specific combinations.
- Mixing with vitamin C — Vitamin C and glutathione together in the same IV are supported by mechanistic synergy (vitamin C regenerates GSH from GSSG) and are commonly co-infused.
- Nebulized reconstitution — Use the compounded product as supplied; do not dilute further without compounding-pharmacy guidance. Nebulizer cleaning between doses matters for preventing infection.
→ Use the Kalios Dosing Calculator for IV / SubQ conversions
Side Effects & Risks
Important
Endogenous tripeptide with well-established biochemistry. Wellness-clinic IV claims are not backed by the acetaminophen-antidote evidence. This is a doctor conversation before routine infusions.
- Generally very well tolerated — Glutathione is an endogenous molecule. Serious adverse effects are rare at normal supplementation doses across oral, IV, and SubQ routes.
- Sulfur odor / taste — Glutathione contains sulfur via its cysteine residue. Some users report a transient sulfurous taste or odor after IV or SubQ administration. Cosmetic, not medical.
- GI effects (oral) — Bloating, cramping, loose stools with standard oral or high-dose liposomal forms. Generally dose-related.
- IV infusion reactions — Rare bronchospasm or flushing at very rapid push rates. Slow 5–10 minute push or 30-minute drip is standard in wellness-clinic protocols.
- Skin lightening (unintended) — For those not seeking skin brightening, the melanin-inhibiting effects may be unwanted — particularly with chronic high-dose IV use. Dose-dependent and reversible after discontinuation.
- Nebulized bronchospasm — Rare. Not common at standard compounded doses. Cystic fibrosis patients should initiate under supervision.
- Serious adverse events in non-medical IV-glutathione skin-whitening — Reports of Stevens-Johnson syndrome, thyroid dysfunction, renal impairment, and anaphylaxis have been associated with uncontrolled high-dose IV glutathione marketed for skin whitening in some jurisdictions. These appear linked to impurities, preservative overload, or extreme dosing rather than therapeutic-dose glutathione itself — but argue for compounded-pharmacy sourcing and supervised administration.
- Zinc-copper imbalance (theoretical) — Chronic very-high-dose glutathione may perturb trace-mineral balance. Long-term high-dose users benefit from baseline zinc, copper, and selenium monitoring.
- Sulfite sensitivity — Some compounded glutathione injectable products contain sulfite preservatives. Sulfite-sensitive patients (a small subset of asthmatics) should confirm formulation.
- Pregnancy / lactation — Insufficient formal data for high-dose supplementation; physiological endogenous glutathione is essential. Avoid high-dose supplementation without clinician guidance.
- Drug interactions — Caution with chemotherapy agents (glutathione may reduce cytotoxicity of some regimens by scavenging ROS). Discuss with oncology team.
Bloodwork & Monitoring
- RBC glutathione or GSH/GSSG ratio — Direct measurement of glutathione status. Available through specialty labs. Most informative biomarker.
- Gamma-glutamyl transferase (GGT) — Liver enzyme involved in glutathione metabolism. Elevated GGT can indicate oxidative stress and increased glutathione demand.
- Liver enzymes (ALT, AST, total bilirubin) — Should remain stable or improve during supplementation.
- hsCRP and oxidative-stress markers — 8-OHdG, F2-isoprostanes, MDA where available. Track improvements in oxidative-stress markers.
- Zinc, copper, selenium — Baseline and at 12 weeks for chronic high-dose users to monitor trace-mineral balance.
- Sulfite sensitivity history — Confirm before compounded IV / SubQ use.
- Renal and thyroid panels — Particularly if adopting the high-dose skin-whitening protocols; case reports have linked uncontrolled dosing to thyroid dysfunction and renal impairment.
Commonly Stacked With
NAD+ — cellular defense stack
NAD+ powers cellular energy while glutathione protects against the oxidative damage that energy production creates. NADPH (derived from NAD+) is also required to recycle oxidized glutathione (GSSG) back to active GSH. These two molecules are deeply interconnected in cellular redox biology.
Vitamin C (IV or oral) — antioxidant synergy
Vitamin C recycles oxidized glutathione back to its active reduced form. Glutathione in turn regenerates oxidized vitamin C. They work in a cooperative antioxidant network. IV vitamin C + glutathione is one of the most common wellness-clinic protocols.
NAC (N-acetylcysteine) — precursor support
NAC provides the rate-limiting cysteine for endogenous glutathione synthesis. Oral NAC 600–1,800 mg/day alongside direct glutathione is a redundant but well-tolerated belt-and-suspenders approach. NAC is FDA-approved as both IV and oral drug (Mucomyst) and widely available as a supplement.
Thymosin Alpha-1 modulates adaptive immunity while glutathione supports innate immune function and provides the antioxidant protection immune cells require. Combined for immune optimization, particularly during illness or chronic infection.
Alpha-lipoic acid (ALA)
Cofactor for mitochondrial dehydrogenases and a disulfide-containing antioxidant that regenerates vitamin C, vitamin E, and glutathione. Synergistic with direct glutathione supplementation; widely used as oral adjunct.
→ Check compound compatibility in the Stack Builder
Practical User Notes
Read This First
Glutathione is accessible through several legitimate channels — supplement, compounded injectable, IV wellness clinic — each with different evidence and appropriate use cases. Uncontrolled high-dose IV skin-whitening protocols marketed outside licensed channels have been associated with serious adverse events; this should not be confused with therapeutic compounded glutathione at standard doses.
- Choose the route that matches the goal — Oral liposomal for baseline antioxidant support. IV or SubQ for rapid replenishment, wellness-clinic protocols, or skin-tone outcomes. Nebulized for respiratory applications. NAC alone if the goal is cheap, oral, well-studied glutathione precursor support.
- Standard oral is not useless — but liposomal is better — Richie 2015 showed standard oral raises body stores at 250–1,000 mg / day. Liposomal formulations achieve the same at lower doses with more predictable absorption.
- IV dosing — go slow — 5–10 minute slow push or 30-minute drip is standard. Very rapid administration has been associated with bronchospasm in rare cases.
- Skin-lightening expectations — The effect is real but modest and dose-dependent. Sonthalia 2018 review: expect gradual lightening over 8–12 weeks of consistent dosing. Reversible on discontinuation. Not a substitute for sunscreen and topical skincare.
- IV wellness-clinic combinations — Glutathione + vitamin C is mechanistically supported (the two antioxidants regenerate each other). Glutathione + NAD+ is mechanistically coherent (NADPH is required to recycle GSSG to GSH). Both combinations are well-tolerated at typical wellness-clinic doses.
- Source with care — Use 503A compounding pharmacies for injectable products. Use reputable supplement brands (NSF, USP, or third-party tested) for oral. Avoid unlicensed high-dose IV skin-whitening products.
- NAC is the cheap alternative — For users who want glutathione support at the lowest cost with the best evidence base, oral NAC 600–1,200 mg / day is the standard.
- Don't expect dramatic changes — Subjective "detox" claims for IV glutathione outpace the evidence. Real effects are modest and cumulative.
- Sulfur note — The characteristic sulfurous odor / taste after injection is normal and transient. Not a sign of impurity.
- Storage — Compounded injectables: refrigerated; discard if yellow or discolored. Oral liposomal: refrigerated after opening; use within the manufacturer's shelf-life window.
- Red flags to stop — Rash, significant bronchospasm, unexpected skin lightening if not desired, new thyroid symptoms, or persistent injection-site reactions.
- Not for self-administration in isolation — Injectable glutathione warrants clinician oversight, particularly for weekly or more frequent dosing.
Regulatory Status
Current Status — April 2026
Glutathione itself is a naturally occurring endogenous molecule and does not hold FDA drug approval as a finished pharmaceutical. It is available through three legitimate pathways: (1) as an oral dietary supplement (standard and liposomal), (2) through 503A / 503B compounding pharmacies for injectable (IV / IM / SubQ) and nebulized use under physician prescription, and (3) as an IV infusion ingredient in licensed wellness / integrative-medicine clinics.
Its precursor N-acetylcysteine (NAC) has FDA drug approval as an oral and IV medication (Acetadote / Mucomyst and generics) for acetaminophen overdose and for use as a mucolytic. NAC was briefly challenged by the FDA in 2020–2022 as a dietary supplement (on the basis that it had been studied as a drug before marketed as a supplement), but FDA enforcement discretion was subsequently exercised and NAC remains widely available as a dietary supplement in the United States.
Glutathione is not among the peptides named in HHS Secretary Robert F. Kennedy Jr.'s February 2026 reclassification announcement because glutathione is not on the FDA Category 2 Bulk Drug Substances list — it has long been available through compounding and supplementation pathways and is not controlled in the way peptide-drug-class substances are.
WADA: Glutathione is not listed on the WADA Prohibited List and is not considered a performance-enhancing substance. Athletes may use without anti-doping concerns.
Cost & Access
Glutathione is accessible through legitimate channels in the United States:
Oral supplement (OTC): Standard reduced-glutathione capsules, liposomal liquid (Quicksilver, Pure Encapsulations, others), and ready-to-use sachets are widely available without prescription at health-food stores and online. No FDA restriction on oral use.
Compounded injectable (prescription): 503A compounding pharmacies produce IV / IM / SubQ glutathione under physician prescription. Wellness clinics, integrative-medicine practices, and some dermatology practices routinely use compounded injectable glutathione. Typical compounded formulations are 200 mg/mL sterile solution.
Nebulized (prescription): Compounded for respiratory applications (cystic fibrosis, chronic respiratory disease) under physician prescription.
NAC precursor (OTC + prescription): N-acetylcysteine is both an FDA-approved drug (Acetadote IV, Mucomyst oral solution) and a widely available OTC dietary supplement at 500–1,000 mg capsule dosing.
Access is stable and long-established; glutathione is not affected by the peptide bulk-substance reclassification debates that apply to BPC-157, GHK-Cu, or the GH secretagogues. Kalios does not sell compounds.
Access and regulatory status as of April 2026. Actual availability varies by provider and jurisdiction. Kalios does not sell compounds.
Related Compounds
People researching Glutathione often also look at these:
Szeto-Schiller peptide (elamipretide). Cardiolipin-targeting mitochondrial membrane stabilizer.
16-amino-acid mitochondrial-encoded peptide. AMPK-activating longevity peptide.
SS-31 + MOTS-c + NAD+ — mitochondrial longevity stack targeting cellular energetics.
Phenothiazine dye and mitochondrial electron-transport alternative carrier. Nootropic and antimicrobial.
Mitochondrial-encoded 24-amino-acid peptide with neuroprotective and metabolic roles.
Key References
- Richie JP Jr, Nichenametla S, Neidig W, Calcagnotto A, Haley JS, Schell TD, Muscat JE. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. 2015;54(2):251-263. PMID: 24791752. (Pivotal oral-glutathione bioavailability RCT.)
- Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. Eur J Clin Pharmacol. 1992;43(6):667-669. PMID: 1362956. (Early skepticism paper documenting poor standard-oral bioavailability.)
- Wu G, Fang YZ, Yang S, Lupton JR, Turner ND. Glutathione metabolism and its implications for health. J Nutr. 2004;134(3):489-492. PMID: 14988435. (Comprehensive metabolic review.)
- Sonthalia S, Daulatabad D, Sarkar R. Glutathione as a skin whitening agent: Facts, myths, evidence and controversies. Indian J Dermatol Venereol Leprol. 2016;82(3):262-272. PMID: 27088927. (Comprehensive skin-lightening evidence review.)
- Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM, Rosati G. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20(7):1159-1170. PMID: 8992335. (Parkinson's IV glutathione pilot.)
- Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord. 2009;24(7):979-983. PMID: 19230029. (Subsequent double-blind placebo-controlled Parkinson's trial — more ambiguous results.)
- Mischley LK, Lau RC, Shankland EG, Wilbur TK, Padowski JM. Phase IIb Study of Intranasal Glutathione in Parkinson's Disease. J Parkinsons Dis. 2017;7(2):289-299. PMID: 28436395. (Intranasal glutathione trial.)
- Weschawalit S, Thongthip S, Phutrakool P, Asawanonda P. Glutathione and its antiaging and antimelanogenic effects. Clin Cosmet Investig Dermatol. 2017;10:147-153. PMID: 28490897.
- Handog EB, Datuin MS, Singzon IA. An open-label, single-arm trial of the safety and efficacy of a novel preparation of glutathione as a skin-lightening agent in Filipino women. Int J Dermatol. 2016;55(2):153-157. PMID: 26471927.
- Arjinpathana N, Asawanonda P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. J Dermatolog Treat. 2012;23(2):97-102. PMID: 20524875.
- Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther. 2014;141(2):150-159. PMID: 24080471.
- Prescott LF, Park J, Ballantyne A, Adriaenssens P, Proudfoot AT. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet. 1977;2(8035):432-434. PMID: 70646. (Foundational NAC-acetaminophen antidote paper.)
- Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med. 2008;359(3):285-292. PMID: 18635433. (Modern clinical review.)
- Bishop C, Hudson VM, Hilton SC, Wilde C. A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest. 2005;127(1):308-317. PMID: 15653999. (Nebulized glutathione in CF.)
- FDA. Acetadote (acetylcysteine) Injection Prescribing Information. FDA.gov. (NAC FDA approval reference for acetaminophen overdose.)
- Lu SC. Regulation of glutathione synthesis. Mol Aspects Med. 2009;30(1-2):42-59. PMID: 18601945. (Cellular glutathione synthesis review.)
- WADA Prohibited List 2026. World Anti-Doping Agency. wada-ama.org. (Glutathione not listed.)
Last updated: April 2026 | Profile authored by Kalios Peptides research team